Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15380664 | 1.00 | DYRK1A (0.33) | DYRK1AADORA2AADORA1IKBKBCHUK | |
| SCHEMBL3126517 | 0.73 | ADORA2A (0.42) | DYRK1AADORA2AADORA1AXLPRKCI | |
| 7-Deazaxanthine SCHEMBL1014230 | 0.72 | DYRK1A (0.40) | DYRK1AADORA2AADORA1IKBKBCHUK | |
| SCHEMBL31514673 | 0.69 | PRKCI (0.41) | DYRK1AADORA2AADORA1AXLPRKCI | |
| SCHEMBL371415 | 0.69 | HRH4 (0.49) | DYRK1AADORA2AADORA1IKBKBCHUK | |
| SCHEMBL5880789 | 0.69 | DYRK1A (0.38) | DYRK1AADORA2AADORA1IKBKBCHUK | |
| SCHEMBL161735 | 0.69 | ADORA2A (0.39) | DYRK1AADORA2AADORA1AXLPRKCI | |
| SCHEMBL18701495 | 0.69 | DYRK1A (0.35) | DYRK1AADORA2AADORA1AXLPRKCI | |
| SCHEMBL30974906 | 0.69 | DYRK1A (0.35) | DYRK1AADORA2AADORA1AXLPRKCI | |
| SCHEMBL14320252 | 0.67 | IKBKB (0.46) | DYRK1AADORA2AADORA1IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | DYRK1A 304/4885ADORA2A 1933/4885ADORA1 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.